Risk-Adjusted NPV Explained: The Gold Standard for Biotech Valuation
Valuing early-stage biotech companies is uniquely challenging. Unlike traditional businesses, these firms often lack revenue, profits, or even products in the market. Instead, their value is tied to scientific innovation, intellectual property, and the uncertain outcome of a years-long clinical and regulatory process. In this environment, traditional valuation methods fall short. Enter risk-adjusted net present […]